Multiple Myeloma Leadership: BMS vs. Janssen in the 2020s
The substantial investments from both pharmaceutical leaders suggest that competitive rivalry between Janssen multiple myeloma therapies and BMS oncology drugs will define industry dynamics for the upcoming decade
